Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Taps Italian Distributor

NEW YORK (GenomeWeb News) – AXA Diagnostics will distribute Rosetta Genomics' microRNA-based miRview line of molecular diagnostic cancer tests in Italy, Rosetta said today.

The exclusive distribution agreement with the Pomezia, Italy-based AXA Diagnostics covers the miRview mets, miRview squamous, and miRview meso tests. AXA will market the tests in Italy, and the samples will be analyzed at Rosetta Genomics' CLIA-certified lab in Philadelphia.

Rosetta Genomics' mets test is used to identify primary tumor site in patients with metastatic cancer and in those with cancer of unknown primary origin. The squamous test differentiates squamous from non-squamous, non-small cell lung cancer patients, and the meso test uses biomarkers to differentiate mesothelioma from other lung carcinomas.

Financial terms of the collaboration were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.